Clinical trial NCT00957918: Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
Official title: Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Parkinson's Disease
Keywords: levodopa-induced dyskinesia
Parkinson's disease
parkinsonian
levodopa-induced dyskinesias in Parkinson's disease
Lead sponsor: Neuraltus Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2009-08-13
Enrollment: 65
Sex: ALL
Minimum age (years): 30
Maximum age (years): 83
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?

Detailed description: Nicotine will be employed at daily doses lower than those available OTC as smoking-cessation patches, in parkinsonian patients experiencing disabling dyskinesias due to their levodopa treatment. The principal adverse effect from this dose level of nicotine is expected to be nausea on acute administration to nicotine-naive patients. Because tolerance to the effects of nicotine is achieved by repeated dose, the study is designed to gradually escalate from 6 to 24 mg per day, taken in 6 separate oral doses of 6 mg each. The study is designed to see if doses which can be tolerated by parkinsonian patients will also reduce the severity and frequency of the dyskinesias experienced following administration of levodopa, the gold standard medication for Parkinson's disease.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of probable idiopathic Parkinson's disease
* in stable health
* male and female aged 30-83 yrs
* Hoehn and Yahr stage II through IV inclusive
* levodopa-induced dyskinesias present greater than 25% of waking day; rating equal or greater than 2 on item 32 of UPDRS
* dyskinesias moderately or severely disabling as determined by a rating of equal or greater than 2 on item 33 of UPDRS
* Mini-Mental state (MMSE) score of equal or greater than 26
* on a stable dose of levodopa for at least 30 days
* if subjects are taking dopamine antagonists, amantadine, MAO-B inhibitors (rasagiline only) or COMT inhibitors, doses must have been stable for at least 30 days

Exclusion Criteria:

* Secondary or non-idiopathic Parkinson's disease
* Subjects with parkinsonian symptoms who do not respond to levodopa therapy
* history of schizophrenia, or other DSM-IV TR axis 1 diagnosis sufficient to interfere with or affect study conduct or interpretation of results
* any history (past 5 years) of suicide or suicide attempt or thoughts or urges of suicide on direct questioning
* subjects who score 2 or higher on a single module of the Jay MIDI scale
* moderate or severe hallucinations, psychoses or delusions
* any medical condition or lab abnormality presenting an unwarranted risk in the opinion of the Investigator
* history of HIV positivity, AIDS, or active hepatitis determined by subject report
* female who is pregnant or breastfeeding
* female of childbearing potential not using double barrier method of birth control throughout the duration of the study
* receipt of a neurosurgical intervention (e.g. brain surgery)related to Parkinson's disease or any neurosurgical procedure sufficient to interfere with study conduct or interpretation of results
* must not have systolic blood pressure ≥150; diastolic ≥95.
* must not have ECG at screening judged clinically significantly abnormal by investigator
* must not have QTc \> 450 msec at ECG screen
* must not have current angina pectoris, history of ventricular arrhythmias, uncontrolled hyperthyroidism, known or suspected pheochromocytoma, symptomatic vasospastic disease, or active peptic ulcer
* must not have a history of stroke, transient ischemic attack (TIA) or myocardial infarction within the last 2 years
* must not have current drug or alcohol abuse within the last two years. Acceptable alcohol use is no more than 3 ounces of alcohol, 3 beers or 2 glasses of wine per day.
* must not be participating in another drug trial or have participated in another drug study in the last 30 days. Observational trials with no intervention are acceptable provided permission is obtained from the other study sponsor in writing.
* must not be unwilling or unable to swallow capsules
* must not have a positive urine test for cotinine at screening
* must not be a smoker, previous (less than 5 years since cessation) smoker or have regular exposure to second hand smoke
* must not be allergic to capsule excipients
* must not be allergic to ondansetron. If allergic, they may participate provided they understand there is no rescue medication for potential nausea or vomiting during the study
* must not have known sensitivity to nicotine or nicotine-containing products
* must not be taking any of the following medications or substances within a minimum of 30 days: nicotine, any form; CYP2A6 inducers or inhibitors during the course of the study or within 30 days of the planned initial dose (your investigator will have a full list of these drugs); Monoamine oxidase inhibitors (with the exception of rasagiline, which is allowed)(your investigator will have a full list of these drugs); apokyn (apomorphine), due to its contraindication with ondansetron); warfarin.

Primary outcomes:
measure: frequency and severity of adverse events, active vs placebo
timeFrame: Every two weeks during dosing (week 0 to week 12) and weekly thereafter for 2 weeks following cessation of dosing
measure: measure of impulse control (rMIDI), active vs placebo
timeFrame: at screening and 4 weeks, 10 weeks, 12 weeks and 14 weeks
Secondary outcomes:
measure: measure of frequency and severity of dyskinesia (USDysRS), active vs placebo
timeFrame: At screen and every two weeks through week 10
measure: Parkinson's disease severity (UPDRS part II,III,IV), active vs placebo
timeFrame: At screen and every two weeks through week 10
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Barrow Neurology Clinics at St. Joseph's Hospital and Medical Center
state: Arizona
city: Los Angelis
country: United States
facility: Keck/USC School of Medicine -Department of Neurology
state: California
city: Oxnard
country: United States
facility: Pacific Neuroscience Medical Group
state: California
city: Englewood
country: United States
facility: Colorado Neurological Institute
state: Colorado
city: Boca Raton
country: United States
facility: Parkinson's Disease & Movement Disorders Ctr of Boca Raton
state: Florida
city: Naples
country: United States
facility: Collier Neurologic Specialists, LLC
state: Florida
city: Golden Valley
country: United States
facility: Strurers Parkinson's Center
state: Minnesota
city: Commack
country: United States
facility: David L. Kreitzman, M.D., P.C.
state: New York
city: Forest Hills
country: United States
facility: 108-14 72nd Ave, Second floor
state: New York
city: Durham
country: United States
facility: Duke University Medical Center, Department of Neurology
state: North Carolina
city: Tusla
country: United States
facility: The Movement Disordedr Clinic of Oklahoma
state: Oklahoma
city: Philadelphia
country: United States
facility: Parkinson's Disease and Movement Center, Penn Comprehensive Neuroscience Center
state: Pennsylvania
Study officials:
affiliation: St. Joseph's Hospital and Medical Center, Barrow Neurology Clinics
name: Abrahan N Lieberman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lieberman A, Lockhart TE, Olson MC, Smith Hussain VA, Frames CW, Sadreddin A, McCauley M, Ludington E. Nicotine Bitartrate Reduces Falls and Freezing of Gait in Parkinson Disease: A Reanalysis. Front Neurol. 2019 May 7;10:424. doi: 10.3389/fneur.2019.00424. eCollection 2019.